persmedРоссийский журнал персонализированной медициныRussian Journal for Personalized Medicine2782-38062782-3814ФОНД АЛМАЗОВА10.18705/2782-3806-2023-3-5-14-21AWYDDGpersmed-192Research ArticleГЕНЕТИЧЕСКИЕ РИСКИ И ПРИЧИНЫ ЗАБОЛЕВАНИЙGENETIC RISKS AND CAUSES OF DISEASESПерсонализированная профилактика: возможности и ограничения оценки полигенного рискаPersonalized prevention: possibilities and limitations of polygenic risk assessmentДрапкинаО. М.DrapkinaO. M.

Драпкина Оксана Михайловна, д.м.н., профессор, академик РАН, директор,

101990, Москва, Петроверигский пер., 10, стр. 3.

Drapkina Oksana M., Ph.D., prof., full member of RAS, Director,

10, bldg 3,  Petroverigsky Lane, Moscow, 101990.

ЛимоноваА. С.LimonovaA. S.

Лимонова Алена Сергеевна, научный сотрудник лаборатории клиномики,

101990, Москва, Петроверигский пер., 10, стр. 3.

Limonova Alena S., research fellow of the clinomic laboratory, 

10, bldg 3,  Petroverigsky Lane, Moscow, 101990.

limonova-alena@yandex.ruГарбузоваЕ. В.GarbuzovaE. V.

Гарбузова Елизавета Владимировна, лаборант-исследователь лаборатории клиномики, 

101990, Москва, Петроверигский пер., 10, стр. 3.

Garbuzova Elizaveta V., laboratory assistant of the clinomic laboratory, 

10, bldg 3,  Petroverigsky Lane, Moscow, 101990.

МешковА. Н.MeshkovA. N.

Мешков Алексей Николаевич, д.м.н., руководитель Института персонализированной терапии и профилактики, 

101990, Москва, Петроверигский пер., 10, стр. 3.

Meshkov Alexey N., Ph.D., head of the institute of personalized therapy and prevention,

10, bldg 3,  Petroverigsky Lane, Moscow, 101990.

ЕршоваА. И.ErshovaA. I.

Ершова Александра Игоревна, д.м.н., заместитель директора по фундаментальной науке, руководитель лаборатории клиномики, 

101990, Москва, Петроверигский пер., 10, стр. 3.

Ershova Alexandra I., Ph.D., head of the clinomic laboratory, deputy director for fundamental science,

10, bldg 3,  Petroverigsky Lane, Moscow, 101990.

Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр терапии и профилактической медицины» Министерства здравоохранения Российской ФедерацииРоссияNational Medical Research Center for Therapy and Preventive MedicineRussian Federation202322112023351421Copyright © Драпкина О.М., Лимонова А.С., Гарбузова Е.В., Мешков А.Н., Ершова А.И., 20232023Драпкина О.М., Лимонова А.С., Гарбузова Е.В., Мешков А.Н., Ершова А.И.Drapkina O.M., Limonova A.S., Garbuzova E.V., Meshkov A.N., Ershova A.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://persmed.elpub.ru/jour/article/view/192

Хронические неинфекционные заболевания (ХНИЗ) составляют основную долю в структуре смертности во всем мире, при этом многие из них имеют многофакторную этиологию, включающую генетические факторы. В связи с этим в рамках создания индивидуальных стратегий профилактики ХНИЗ представляется перспективным проведение генетического тестирования с оценкой полигенного риска с помощью шкал генетического риска (ШГР). В настоящем обзоре будут рассмотрены ШГР различных ХНИЗ, их особенности и возможности применения.

Noncommunicable diseases (NCDs) are the leading cause of mortality worldwide, with a vast majority of them having a multifactorial etiology, including genetics. That is why implementation of polygenic risk scores (PRS) in clinical practice with the aim of development of individual strategies for NCDs prevention seems promising. In this review we will discuss development and possible implications of PRSs.

артериальная гипертензияатеросклерозгиперлипидемияишемическая болезнь сердцаожирениепрофилактикасахарный диабет 2 типахронические неинфекционные заболеванияшкала генетического рискаatherosclerosiscoronary artery diseasehyperlipidemiahypertensionnoncommunicable diseasesobesitypolygenic risk scorepreventiontype 2 diabetes mellitusReferencesNoncommunicable diseases. Global Health Estimates: Life expectancy and leading causes of death and disability. https://www.who.int/data/gho/data/themes/topics/topic-details/GHO/ncd-mortality (22 August 2023).Noncommunicable diseases. Global Health Estimates: Life expectancy and leading causes of death and disability. https://www.who.int/data/gho/data/themes/topics/topic-details/GHO/ncd-mortality (22 August 2023).Копылова О.В., Ершова А.И., Мешков А.Н., Драпкина О.М. Профилактика сердечно-сосудистых заболеваний на протяжении жизни. Часть 1: преконцепционный, пренатальный и грудной периоды. КВТиП. 2020;19(6):2647.Kopylova OV, Ershova AI, Meshkov AN, et al. Lifelong prevention of cardiovascular disease. Part I: preconceptional, prenatal and infant periods of life. Cardiovascular Therapy and Prevention. 2020;19(6):2647. (In Russian)Lewis C, Vassos E. Polygenic risk scores: from research tools to clinical instruments. Genome Med. 2020;12(1):44. DOI:10.1186/s13073-020-00742-5.Lewis C, Vassos E. Polygenic risk scores: from research tools to clinical instruments. Genome Med. 2020;12(1):44. DOI:10.1186/s13073-020-00742-5.Choi SW, Mak TSH, O’Reilly PF. Tutorial: a guide to performing polygenic risk score analyses. Nat Protoc. 2020;15(9):2759–2772.Choi SW, Mak TSH, O’Reilly PF. Tutorial: a guide to performing polygenic risk score analyses. Nat Protoc. 2020;15(9):2759–2772.Franzago M, Santurbano D, Vitacolonna E, Stuppia L. Genes and Diet in the Prevention of Chronic Diseases in Future Generations. Int J Mol Sci. 2020;21(7).Franzago M, Santurbano D, Vitacolonna E, Stuppia L. Genes and Diet in the Prevention of Chronic Diseases in Future Generations. Int J Mol Sci. 2020;21(7).Мешков А.Н., Щербакова Н.В. Молекулярно-генетическая диагностика предрасположенности к развитию ишемической болезни сердца: современное состояние проблемы. Consilium Medicum. 2016;18:22–26.Meshkov AN, Shcherbakova NV. Molecular genetic diagnosis of predisposition to the development of coronary heart disease: modern state of the problem. Consilium Medicum. 2016;18:22–26. (In Russian)Inouye M, Abraham G, Nelson CP, et al. Genomic Risk Prediction of Coronary Artery Disease in 480,000 Adults: Implications for Primary Prevention. J Am Coll Cardiol. 2018;72(16):1883–1893.Inouye M, Abraham G, Nelson CP, et al. Genomic Risk Prediction of Coronary Artery Disease in 480,000 Adults: Implications for Primary Prevention. J Am Coll Cardiol. 2018;72(16):1883–1893.Khera AV, Chaffin M, Aragam KG, et al. Genomewide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet. 2018;50(9):1219–1224.Khera AV, Chaffin M, Aragam KG, et al. Genomewide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet. 2018;50(9):1219–1224.Khera AV, Emdin CA, Drake I, et al. Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease. N Engl J Med. 2016;375(24):2349–2358.Khera AV, Emdin CA, Drake I, et al. Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease. N Engl J Med. 2016;375(24):2349–2358.Hasbani NR, Ligthart S, Brown MR, et al. American Heart Association’s Life’s Simple 7: Lifestyle Recommendations, Polygenic Risk, and Lifetime Risk of Coronary Heart Disease. Circulation. 2022;145(11):808–818.Hasbani NR, Ligthart S, Brown MR, et al. American Heart Association’s Life’s Simple 7: Lifestyle Recommendations, Polygenic Risk, and Lifetime Risk of Coronary Heart Disease. Circulation. 2022;145(11):808–818.Klarin D, Damrauer SM, Tsao PS, et al. Genetic Architecture of Abdominal Aortic Aneurysm in the Million Veteran Program. Circulation. 2020;142(17):1633–1646.Klarin D, Damrauer SM, Tsao PS, et al. Genetic Architecture of Abdominal Aortic Aneurysm in the Million Veteran Program. Circulation. 2020;142(17):1633–1646.Natarajan P, Young R, Stitziel NO, et al. Polygenic Risk Score Identifies Subgroup With Higher Burden of Atherosclerosis and Greater Relative Benefit From Statin Therapy in the Primary Prevention Setting. Circulation. 2017;135(22):2091–2101.Natarajan P, Young R, Stitziel NO, et al. Polygenic Risk Score Identifies Subgroup With Higher Burden of Atherosclerosis and Greater Relative Benefit From Statin Therapy in the Primary Prevention Setting. Circulation. 2017;135(22):2091–2101.den Hoed M, Strawbridge RJ, Almgren P, et al. GWASidentified loci for coronary heart disease are associated with intima-media thickness and plaque presence at the carotid artery bulb. Atherosclerosis. 2015;239(2):304–310.den Hoed M, Strawbridge RJ, Almgren P, et al. GWASidentified loci for coronary heart disease are associated with intima-media thickness and plaque presence at the carotid artery bulb. Atherosclerosis. 2015;239(2):304–310.Trinder M, Francis GA, Brunham LR. Association of Monogenic vs Polygenic Hypercholesterolemia With Risk of Atherosclerotic Cardiovascular Disease. JAMA Cardiol. 2020;5(4):390–399.Trinder M, Francis GA, Brunham LR. Association of Monogenic vs Polygenic Hypercholesterolemia With Risk of Atherosclerotic Cardiovascular Disease. JAMA Cardiol. 2020;5(4):390–399.Futema M, Taylor-Beadling A, Williams M, et al. Genetic testing for familial hypercholesterolemia-past, present, and future. J Lipid Res. 2021;62:100139.Futema M, Taylor-Beadling A, Williams M, et al. Genetic testing for familial hypercholesterolemia-past, present, and future. J Lipid Res. 2021;62:100139.Trinder M, Paquette M, Cermakova L, et al. Polygenic Contribution to Low-Density Lipoprotein Cholesterol Levels and Cardiovascular Risk in Monogenic Familial Hypercholesterolemia. Circ Genomic Precis Med. 2020;13(5):515–523.Trinder M, Paquette M, Cermakova L, et al. Polygenic Contribution to Low-Density Lipoprotein Cholesterol Levels and Cardiovascular Risk in Monogenic Familial Hypercholesterolemia. Circ Genomic Precis Med. 2020;13(5):515–523.Marston NA, Kamanu FK, Nordio F, et al. Predicting Benefit FromEvolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score: Results From the FOURIER Trial. Circulation. 2020;141(8):616–623.Marston NA, Kamanu FK, Nordio F, et al. Predicting Benefit FromEvolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score: Results From the FOURIER Trial. Circulation. 2020;141(8):616–623.Vanhoye X, Bardel C, Rimbert A, et al. A new 165-SNP low-density lipoprotein cholesterol polygenic risk score based on next generation sequencing outperforms previously published scores in routine diagnostics of familial hypercholesterolemia. Transl Res. 2023;255:119–127.Vanhoye X, Bardel C, Rimbert A, et al. A new 165-SNP low-density lipoprotein cholesterol polygenic risk score based on next generation sequencing outperforms previously published scores in routine diagnostics of familial hypercholesterolemia. Transl Res. 2023;255:119–127.Лимонова А.С., Ершова А.И., Киселева А.В. и др. Оценка полигенного риска артериальной гипертензии. Кардиоваскулярная терапия и профилактика. 2022;21(12):3464.Limonova AS, Ershova AI, Kiseleva AV, et al. Assessment of polygenic risk of hypertension. Kardiovaskulyarnaya terapiya i profilaktika. 2022;21(12):3464. (In Russian)Giontella A, Sjögren M, Lotta LA, et al. Clinical Evaluation of the Polygenetic Background of Blood Pressure in the PopulationBased Setting. Hypertension. 2020;77:169–77.Giontella A, Sjögren M, Lotta LA, et al. Clinical Evaluation of the Polygenetic Background of Blood Pressure in the PopulationBased Setting. Hypertension. 2020;77:169–77.Vaura F, Kauko A, Suvila K, et al. Polygenic risk scores predict hypertension onset and cardiovascular risk. Hypertension. 2021:1119–27.Vaura F, Kauko A, Suvila K, et al. Polygenic risk scores predict hypertension onset and cardiovascular risk. Hypertension. 2021:1119–27.Sun X, Pan Y, Zhang R, et al. Life-Course Associations between Blood Pressure-Related Polygenic Risk Scores and Hypertension in the Bogalusa Heart Study. Genes (Basel). 2022;13(8).Sun X, Pan Y, Zhang R, et al. Life-Course Associations between Blood Pressure-Related Polygenic Risk Scores and Hypertension in the Bogalusa Heart Study. Genes (Basel). 2022;13(8).Malik R, Chauhan G, Traylor M, et al. Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. Nat Genet. 2018;50(4):524–537.Malik R, Chauhan G, Traylor M, et al. Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. Nat Genet. 2018;50(4):524–537.Rutten-Jacobs LC, Larsson SC, Malik R, et al. Genetic risk, incident stroke, and the benefits of adhering to a healthy lifestyle: cohort study of 306473 UK Biobank participants. BMJ. 2018;363:k4168.Rutten-Jacobs LC, Larsson SC, Malik R, et al. Genetic risk, incident stroke, and the benefits of adhering to a healthy lifestyle: cohort study of 306473 UK Biobank participants. BMJ. 2018;363:k4168.Marston NA, Patel PN, Kamanu FK, et al. Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease. Circulation. 2021;143(5):470–478.Marston NA, Patel PN, Kamanu FK, et al. Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease. Circulation. 2021;143(5):470–478.Khera AV, Chaffin M, Aragam KG, et al. Genomewide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet. 2018;50(9):1219–1224.Khera AV, Chaffin M, Aragam KG, et al. Genomewide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet. 2018;50(9):1219–1224.Yun JS, Jung SH, Shivakumar M, et al. Polygenic risk for type 2 diabetes, lifestyle, metabolic health, and cardiovascular disease: a prospective UK Biobank study. Cardiovasc Diabetol 21, 131 (2022).Yun JS, Jung SH, Shivakumar M, et al. Polygenic risk for type 2 diabetes, lifestyle, metabolic health, and cardiovascular disease: a prospective UK Biobank study. Cardiovasc Diabetol 21, 131 (2022).Ge T, Irvin MR, Patki A, et al. Development and validation of a trans-ancestry polygenic risk score for type 2 diabetes in diverse populationns. Genome Med 14, 70 (2022).Ge T, Irvin MR, Patki A, et al. Development and validation of a trans-ancestry polygenic risk score for type 2 diabetes in diverse populationns. Genome Med 14, 70 (2022).Li JH, Szczerbinski L, Dawed AY, et al. A polygenic score for type 2 diabetes risk is associated with both the acute and sustained response to sulfonylureas. Diabetes. 2021;70:293–300.Li JH, Szczerbinski L, Dawed AY, et al. A polygenic score for type 2 diabetes risk is associated with both the acute and sustained response to sulfonylureas. Diabetes. 2021;70:293–300.Finer N. Medical consequences of obesity. Medicine. 2015;43(2):88–93.Finer N. Medical consequences of obesity. Medicine. 2015;43(2):88–93.Khera AV, Chaffin M, Wade KH, et al. Polygenic Prediction of Weight and Obesity Trajectories from Birth to Adulthood. Cell. 2019 Apr 18;177(3):587–596.e9.Khera AV, Chaffin M, Wade KH, et al. Polygenic Prediction of Weight and Obesity Trajectories from Birth to Adulthood. Cell. 2019 Apr 18;177(3):587–596.e9.Dashti HS, Miranda N, Cade BE, et al. Interaction of obesity polygenic score with lifestyle risk factors in an electronic health record biobank. BMC Med 20, 5 (2022).Dashti HS, Miranda N, Cade BE, et al. Interaction of obesity polygenic score with lifestyle risk factors in an electronic health record biobank. BMC Med 20, 5 (2022).Dudbridge F. Power and predictive accuracy of polygenic risk scores. PLoS Genet. 2013;9(3):e1003348.Dudbridge F. Power and predictive accuracy of polygenic risk scores. PLoS Genet. 2013;9(3):e1003348.Manolio TA, Collins FS, Cox NJ, et al. Finding the missing heritability of complex diseases. Nature. 2009;461(7265):747.Manolio TA, Collins FS, Cox NJ, et al. Finding the missing heritability of complex diseases. Nature. 2009;461(7265):747.Igo RP, Kinzy TG, Cooke Bailey JN. Genetic Risk Scores. CurrProtoc Hum Genet. 2019;104(1):e95.Igo RP, Kinzy TG, Cooke Bailey JN. Genetic Risk Scores. CurrProtoc Hum Genet. 2019;104(1):e95.Martin AR, Gignoux CR, Walters RK, et al. Human Demographic History Impacts Genetic Risk Prediction across Diverse Populations. Am J Hum Genet. 2017;100(4):635.Martin AR, Gignoux CR, Walters RK, et al. Human Demographic History Impacts Genetic Risk Prediction across Diverse Populations. Am J Hum Genet. 2017;100(4):635.Dron JS, Hegele RA. The evolution of geneticbased risk scores for lipids and cardiovascular disease. CurrOpinLipidol. 2019;30(2):71–81.Dron JS, Hegele RA. The evolution of geneticbased risk scores for lipids and cardiovascular disease. CurrOpinLipidol. 2019;30(2):71–81.Wand H, Lambert SA, Tamburro C, et al. Improving reporting standards for polygenic scores in risk prediction studies. Nature. 2021;591(7849):211–219.Wand H, Lambert SA, Tamburro C, et al. Improving reporting standards for polygenic scores in risk prediction studies. Nature. 2021;591(7849):211–219.

The authors declare that there are no conflicts of interest present.